Stay updated on FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Sign up to get notified when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.

Latest updates to the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page
- Check7 days agoChange DetectedNo additions or deletions are observed between the two screenshots; the page content and layout appear unchanged.SummaryDifference0.0%

- Check14 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3, representing a minor metadata update.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check35 days agoChange DetectedThe changes consist of an internal software revision update from v3.4.1 to v3.4.2; no content related to the study details, eligibility, or results appears to be altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check43 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; this is a minor metadata change with no impact on the study details or functionality.SummaryDifference0.0%

- Check65 days agoChange DetectedRevision: v3.3.3 updated to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check86 days agoChange DetectedAdded a Results Submitted status and expanded the Locations section to include multiple study sites across the United States and Australia. The expanded location list includes Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts, Michigan, New Mexico, New York, North Carolina, Texas, Washington, Victoria, and Western Australia.SummaryDifference2%

Stay in the know with updates to FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.